{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:27:48Z","timestamp":1790749668872,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R15CA159308"],"award-info":[{"award-number":["R15CA159308"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP101042"],"award-info":[{"award-number":["RP101042"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ceramide synthases (CERS) produce ceramides which are key intermediators in the biosynthesis of complex sphingolipids and play an important role in cell proliferation, differentiation, apoptosis and senescence. CERS6 is an isoform of ceramide synthases known to generate ceramides with C16 acyl chain (C<jats:sub>16<\/jats:sub>-Cer). CERS6 and C<jats:sub>16<\/jats:sub>-Cer levels were significantly higher in acute lymphoblastic leukemia (ALL) cells in comparison to peripheral blood mononuclear cells and T lymphocytes derived from healthy human volunteers. We investigated the role of CERS6 in chemo-resistance in T-ALL cell lines. Stable knockdown of<jats:italic>CERS6<\/jats:italic>in CCRF-CEM and MOLT-4 cells resulted in increased sensitivity to ABT-737, a pan-BCL-2 inhibitor, while CCRF-CEM cells with exogenous<jats:italic>CERS6<\/jats:italic>expression showed resistance to ABT-737 relative to the vector control. The cytotoxic activity of ABT-737 in<jats:italic>CERS6<\/jats:italic>knockdown cells was significantly reduced by the addition of a caspase-8 inhibitor Z-IETD, suggesting that CERS6 alters the cytotoxicity via extrinsic pathway of apoptosis. By co-immunoprecipitation of CERS6 in CCRF-CEM cells, we identified CD95\/Fas, a mediator of extrinsic apoptotic pathway, as a novel CERS6 binding partner. In Fas pull-down samples, FADD (Fas-associated protein with death domain) was detected at higher levels in cells with<jats:italic>CERS6<\/jats:italic>knockdown compared with control cells when treated with ABT-737, and this was reversed by the overexpression of<jats:italic>CERS6<\/jats:italic>, demonstrating that CERS6 interferes with Fas\u2013FADD DISC assembly. CERS6 may serve as a biomarker in determining the effectiveness of anticancer agents acting via the extrinsic pathway in T-ALL.<\/jats:p>","DOI":"10.1038\/s41419-018-0964-4","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T09:22:19Z","timestamp":1536657739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95\/Fas in T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8092-1528","authenticated-orcid":false,"given":"Dattesh","family":"Verlekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Jen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9220-7225","authenticated-orcid":false,"given":"Hwangeui","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min H.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"964_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10\u201329 (2012).","journal-title":"CA Cancer J. Clin."},{"key":"964_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui, C. H., Robison, L. L. & Look, A. T. Acute lymphoblastic leukaemia. Lancet 371, 1030\u20131043 (2008).","journal-title":"Lancet"},{"key":"964_CR3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger, S. P. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 30, 1663\u20131669 (2012).","journal-title":"J. Clin. Oncol."},{"key":"964_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters, R. et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 370, 240\u2013250 (2007).","journal-title":"Lancet"},{"key":"964_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","volume":"95","author":"A Oriol","year":"2010","unstructured":"Oriol, A. et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 95, 589\u2013596 (2010).","journal-title":"Haematologica"},{"key":"964_CR6","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","volume":"360","author":"CH Pui","year":"2009","unstructured":"Pui, C. H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730\u20132741 (2009).","journal-title":"N. Engl. J. Med."},{"key":"964_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrm2329","volume":"9","author":"YA Hannun","year":"2008","unstructured":"Hannun, Y. A. & Obeid, L. M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9, 139\u2013150 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"964_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc1411","volume":"4","author":"B Ogretmen","year":"2004","unstructured":"Ogretmen, B. & Hannun, Y. A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4, 604\u2013616 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"964_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1042\/BJ20111626","volume":"441","author":"TD Mullen","year":"2012","unstructured":"Mullen, T. D., Hannun, Y. A. & Obeid, L. M. Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem. J. 441, 789\u2013802 (2012).","journal-title":"Biochem. J."},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canlet.2003.08.034","volume":"206","author":"CP Reynolds","year":"2004","unstructured":"Reynolds, C. P., Maurer, B. J. & Kolesnick, R. N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 206, 169\u2013180 (2004).","journal-title":"Cancer Lett."},{"key":"964_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/iub.314","volume":"62","author":"M Levy","year":"2010","unstructured":"Levy, M. & Futerman, A. H. Mammalian ceramide synthases. IUBMB Life 62, 347\u2013356 (2010).","journal-title":"IUBMB Life"},{"key":"964_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.14348\/molcells.2015.0118","volume":"38","author":"K Kitatani","year":"2015","unstructured":"Kitatani, K., Taniguchi, M. & Okazaki, T. Role of sphingolipids and metabolizing enzymes in hematological malignancies. Mol. Cells 38, 482\u2013495 (2015).","journal-title":"Mol. Cells"},{"key":"964_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jms.1696","volume":"45","author":"D Ghosh","year":"2010","unstructured":"Ghosh, D., Lippert, D., Krokhin, O., Cortens, J. P. & Wilkins, J. A. Defining the membrane proteome of NK cells. J. Mass Spectrom. 45, 1\u201325 (2010).","journal-title":"J. Mass Spectrom."},{"key":"964_CR14","first-page":"905","volume":"16","author":"A Weinmann","year":"2005","unstructured":"Weinmann, A., Galle, P. R. & Teufel, A. LASS6, an additional member of the longevity assurance gene family. Int. J. Mol. Med. 16, 905\u2013910 (2005).","journal-title":"Int. J. Mol. Med."},{"key":"964_CR15","doi-asserted-by":"publisher","first-page":"21433","DOI":"10.1074\/jbc.M113.479907","volume":"288","author":"P Ebel","year":"2013","unstructured":"Ebel, P. et al. Inactivation of ceramide synthase 6 in mice results in an altered sphingolipid metabolism and behavioral abnormalities. J. Biol. Chem. 288, 21433\u201321447 (2013).","journal-title":"J. Biol. Chem."},{"key":"964_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/onc.2008.468","volume":"28","author":"S White-Gilbertson","year":"2009","unstructured":"White-Gilbertson, S. et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 28, 1132\u20131141 (2009).","journal-title":"Oncogene"},{"key":"964_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1096\/fj.09-135087","volume":"24","author":"CE Senkal","year":"2010","unstructured":"Senkal, C. E., Ponnusamy, S., Bielawski, J., Hannun, Y. A. & Ogretmen, B. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6\/CHOP arm of ER-stress-response pathways. FASEB J. 24, 296\u2013308 (2010).","journal-title":"FASEB J."},{"key":"964_CR18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541\u20131552 (2015).","journal-title":"N. Engl. J. Med."},{"key":"964_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166\u2013178 (2006).","journal-title":"N. Engl. J. Med."},{"key":"964_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677\u2013681 (2005).","journal-title":"Nature"},{"key":"964_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","volume":"15","author":"MH Kang","year":"2009","unstructured":"Kang, M. H. & Reynolds, C. P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 15, 1126\u20131132 (2009).","journal-title":"Clin. Cancer Res."},{"key":"964_CR22","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","volume":"26","author":"D Chauhan","year":"2007","unstructured":"Chauhan, D. et al. A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26, 2374\u20132380 (2007).","journal-title":"Oncogene"},{"key":"964_CR23","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","volume":"110","author":"MH Kang","year":"2007","unstructured":"Kang, M. H. et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110, 2057\u20132066 (2007).","journal-title":"Blood"},{"key":"964_CR24","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1158\/1078-0432.CCR-07-5090","volume":"14","author":"G Neale","year":"2008","unstructured":"Neale, G. et al. Molecular characterization of the pediatric preclinical testing panel. Clin. Cancer Res. 14, 4572\u20134583 (2008).","journal-title":"Clin. Cancer Res."},{"key":"964_CR25","doi-asserted-by":"publisher","first-page":"e74768","DOI":"10.1371\/journal.pone.0074768","volume":"8","author":"MW Holliday Jr","year":"2013","unstructured":"Holliday, M. W. Jr, Cox, S. B., Kang, M. H. & Maurer, B. J. C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines. PLoS One 8, e74768 (2013).","journal-title":"PLoS One"},{"key":"964_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0005-2760(88)90030-6","volume":"959","author":"PP Van Veldhoven","year":"1988","unstructured":"Van Veldhoven, P. P. & Bell, R. M. Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cells. Biochim. Biophys. Acta 959, 185\u2013196 (1988).","journal-title":"Biochim. Biophys. Acta"},{"key":"964_CR27","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1021\/bi061994u","volume":"46","author":"X Wang","year":"2007","unstructured":"Wang, X. et al. Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry 46, 3553\u20133565 (2007).","journal-title":"Biochemistry"},{"key":"964_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s13238-013-0018-8","volume":"5","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. DSSylation, a novel protein modification targets proteins induced by oxidative stress, and facilitates their degradation in cells. Protein Cell 5, 124\u2013140 (2014).","journal-title":"Protein Cell"},{"key":"964_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/pbc.22801","volume":"56","author":"MH Kang","year":"2011","unstructured":"Kang, M. H. et al. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr. Blood Cancer 56, 239\u2013249 (2011).","journal-title":"Pediatr. Blood Cancer"},{"key":"964_CR30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/jnci\/djn076","volume":"100","author":"MH Kang","year":"2008","unstructured":"Kang, M. H., Wan, Z., Kang, Y. H., Sposto, R. & Reynolds, C. P. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J. Natl. Cancer Inst. 100, 580\u2013595 (2008).","journal-title":"J. Natl. Cancer Inst."},{"key":"964_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1535-7163.MCT-16-0749","volume":"16","author":"MR Makena","year":"2017","unstructured":"Makena, M. R., Koneru, B., Nguyen, T. H., Kang, M. H. & Reynolds, C. P. Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies. Mol. Cancer Ther. 16, 649\u2013661 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"964_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc3398","volume":"13","author":"SA Morad","year":"2013","unstructured":"Morad, S. A. & Cabot, M. C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 13, 51\u201365 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"964_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1074-7613(00)80212-5","volume":"12","author":"FC Kischkel","year":"2000","unstructured":"Kischkel, F. C. et al. Apo2L\/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611\u2013620 (2000).","journal-title":"Immunity"},{"key":"964_CR34","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1002\/j.1460-2075.1995.tb00245.x","volume":"14","author":"FC Kischkel","year":"1995","unstructured":"Kischkel, F. C. et al. Cytotoxicity-dependent APO-1 (Fas\/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579\u20135588 (1995).","journal-title":"EMBO J."},{"key":"964_CR35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/cdd.2014.153","volume":"22","author":"A Rossin","year":"2015","unstructured":"Rossin, A. et al. Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability. Cell Death Differ. 22, 643\u2013653 (2015).","journal-title":"Cell Death Differ."},{"key":"964_CR36","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3109\/10428194.2011.568653","volume":"52","author":"A Camgoz","year":"2011","unstructured":"Camgoz, A., Gencer, E. B., Ural, A. U., Avcu, F. & Baran, Y. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells. Leuk. Lymphoma 52, 1574\u20131584 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"964_CR37","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.bbalip.2014.09.006","volume":"1841","author":"AB Shakor","year":"2014","unstructured":"Shakor, A. B. et al. Curcumin induces apoptosis of multidrug-resistant human leukemia HL60 cells by complex pathways leading to ceramide accumulation. Biochim. Biophys. Acta 1841, 1672\u20131682 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"964_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/carcin\/bgp061","volume":"30","author":"S Schiffmann","year":"2009","unstructured":"Schiffmann, S. et al. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 30, 745\u2013752 (2009).","journal-title":"Carcinogenesis"},{"key":"964_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10549-007-9836-9","volume":"112","author":"E Ruckhaberle","year":"2008","unstructured":"Ruckhaberle, E. et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat. 112, 41\u201352 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"964_CR40","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1172\/JCI79775","volume":"126","author":"M Suzuki","year":"2016","unstructured":"Suzuki, M. et al. Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells. J. Clin. Invest. 126, 254\u2013265 (2016).","journal-title":"J. Clin. Invest."},{"key":"964_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.canlet.2007.06.003","volume":"256","author":"S Karahatay","year":"2007","unstructured":"Karahatay, S. et al. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 256, 101\u2013111 (2007).","journal-title":"Cancer Lett."},{"key":"964_CR42","doi-asserted-by":"publisher","first-page":"25003","DOI":"10.1074\/jbc.M802511200","volume":"283","author":"JH Song","year":"2008","unstructured":"Song, J. H., Kandasamy, K. & Kraft, A. S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 283, 25003\u201325013 (2008).","journal-title":"J. Biol. Chem."},{"key":"964_CR43","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.4049\/jimmunol.163.9.4909","volume":"163","author":"M Woo","year":"1999","unstructured":"Woo, M. et al. In vivo evidence that caspase-3 is required for Fas-mediated apoptosis of hepatocytes. J. Immunol. 163, 4909\u20134916 (1999).","journal-title":"J. Immunol."},{"key":"964_CR44","doi-asserted-by":"publisher","first-page":"5682","DOI":"10.1073\/pnas.1316700111","volume":"111","author":"SA Jensen","year":"2014","unstructured":"Jensen, S. A. et al. Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc. Natl Acad. Sci. USA 111, 5682\u20135687 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"964_CR45","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1074\/jbc.M115.668228","volume":"291","author":"SA Novgorodov","year":"2016","unstructured":"Novgorodov, S. A. et al. SIRT3 deacetylates ceramide synthases: implications for mitochondrial dysfunction and brain injury. J. Biol. Chem. 291, 1957\u20131973 (2016).","journal-title":"J. Biol. Chem."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0964-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0964-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0964-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T05:20:44Z","timestamp":1720588844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0964-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0964-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"925"}}